Related Experiment Videos
Methotrexate: new mechanisms and old toxicities
1Virginia Mason Research Center, Seattle, Washington.
Agents and Actions. Supplements
|January 1, 1993
Summary
Methotrexate, a disease-modifying antirheumatic drug (DMARD), shows potent anti-inflammatory effects and may alter rheumatoid arthritis progression. Its efficacy rivals gold, but toxicities like cirrhosis and pneumonitis require monitoring.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Methotrexate (MTX) is a widely used second-line agent for rheumatoid arthritis.
- Evolving research clarifies MTX's mechanisms of action, efficacy, and toxicity profiles.
Purpose of the Study:
- To summarize current understanding of methotrexate's anti-inflammatory mechanisms.
- To review MTX efficacy in rheumatoid arthritis compared to other agents.
- To document MTX-associated toxicities and drug interactions.
Main Methods:
- Literature review and meta-analysis data synthesis.
- Analysis of pharmacokinetic and pharmacodynamic properties.
- Documentation of reported adverse events and drug interactions.
Main Results:
- Methotrexate demonstrates potent anti-inflammatory effects via LTB4 and adenosine release.
- A meta-analysis indicated MTX efficacy in inhibiting radiographic erosions, comparable to gold and superior to azathioprine.
- Documented toxicities include cirrhosis (0.1-0.2% incidence) and pneumonitis. NSAID-MTX interactions are noted, with controversial mechanisms.
Conclusions:
- Methotrexate is a highly effective anti-rheumatic agent with significant anti-inflammatory properties.
- Careful monitoring for toxicities such as cirrhosis and pneumonitis is essential.
- Further research is needed to elucidate NSAID-MTX interaction mechanisms.